---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-082237"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:26:08.098016+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oramed signs $11.5M CRO agreement for Phase 3 trial of ORMD-0801 in type 2 diabetes

## Summary
- Oramed Ltd. subsidiary retained InClin as CRO for planned Phase 3 trial of oral insulin candidate ORMD-0801.
- Trial to assess safety/efficacy in approximately 300 type 2 diabetes patients under US IND.
- Total consideration up to ~$11.5 million, paid monthly based on hours performed over engagement.
- Sponsor can terminate with or without cause on 30 days' notice; standard cure period for breach.

## SEC filing metadata
- accession: 0001213900-24-082237
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390024082237/0001213900-24-082237-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390024082237/ea0215648-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-082237
- JSON: https://secwatch.observer/filing/0001213900-24-082237.json
- Plain text: https://secwatch.observer/filing/0001213900-24-082237.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.